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Human platelet-derived growth factor-BB (hPDGF-BB) is a basic polypeptide growth factor released from platelets at the injury
site.ItisamultifunctionalmoleculethatregulatesDNAsynthesisandcelldivisionandinducesbiologicaleﬀectsthatareimplicated
in tissue repair, atherosclerosis, inﬂammatory responses, and neoplastic diseases. This paper is an overview of the toxicology
data generated from a broad testing platform to determine bone, soft tissue, and systemic responses following administration of
rhPDGF-BB.Moreover,thesystemicandlocaltoxicityofrecombinanthumanPDGF-BB(rhPDGF-BB)incombinationwitheither
beta-tricalcium phosphate (β-TCP) or collagen combined with β-TCP was studied to determine dermal sensitization, irritation,
intramuscular tissue responses, pyrogenicity, genotoxicity, and hemolytic properties. All data strongly suggest that rhPDGF-BB
either alone or in combination with β-TCP or collagen with β-TCP is biocompatible and has neither systemic nor local toxicity,
supporting its safe use in enhancing wound healing in patients.
1.Introduction
Human platelet-derived growth factor-BB (hPDGF-BB) is
a basic polypeptide growth factor released from platelets
[1]. PDGF initiates wound healing and is chemotactic and
mitogenic for mesenchymal cells that can diﬀerentiate to
osteoblasts, chondrocytes and vascular smooth muscle cells
[2–5]. Moreover, PDGF-BB is proangiogenic and upreg-
ulates vascular endothelial growth factor (VEGF) [4–6].
These properties are profoundly important for homeostasis
and regeneration of bone and soft tissues. Consequently,
PDGF-BB is a compelling therapeutic to enhance tissue
wound healing.
Recombinant human PDGF-BB (rhPDGF-BB) has been
combinedwithbiocompatible,osteoconductiveβ-tricalcium
phosphate (β-TCP) to regenerate periodontal tissue [7, 8].
Further, rhPDGF-BB combined with β-TCP is approved by
the Food and Drug Administration (FDA) in the United
States and Health Canada in Canada for the treatment of
periodontal tissues and is available commercially under the
trade name GEM 21S (Luitpold, NY).
In addition, clinical studies are underway in the United
States,Europe,andCanadatoestablishthesafetyandeﬃcacy
of rhPDGF-BB/β-TCP (Augment Bone Graft) for orthopedic
applications. A combination of rhPDGF-BB and a solu-
ble bovine type I collagen combined with β-TCP matrix2 Journal of Tissue Engineering
(Augment Injectable Bone Graft) formulated as an injectable
paste, is under development. Furthermore, rhPDGF-BB in
a topical gel matrix is FDA-approved to treat diabetic skin
ulcers (Regranex, Ortho-McNeil/Johnson, and Johnson).
Although the safety of rhPDGF-BB has been established
through various clinical applications for dermal and per-
iodontal tissue healing, new combinations of the protein
with other materials could lead to unique safety outcomes
compared to using the protein alone, or when combined
with materials for which there is an established clinical safety
proﬁle. Thus, the purpose of this paper is to provide an
overview of the preclinical animal toxicology supporting the
safe use of rhPDGF-BB in combination with β-TCP and
a soluble type I collagen matrix, which represent unique
combination products for treating indications involving
orthopaedic bone repair.
2.MaterialsandMethods
Testingwasconductedinaccordancewithguidanceprovided
by the International Organization for Standardization (ISO)
and United States Pharmacopeia (USP) for the evaluation of
the biocompatibility of medical devices. Moreover, animal
work was done at facilities accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) under protocols approved by Institutional
Animal Care and Use Committee (IACUC) review boards.
All aspects of the studies described below were conducted
using Good Laboratory Practices (GLP). A summary of the
t e s t sp r e f o r m e do ne a c ht y p eo fd e l i v e r ys y s t e mf o rP D G Fi s
included in Table 1.
Recombinant human PDGF-BB (rhPDGF-BB) was pro-
vided by BioMimetic Therapeutics, Inc. (Franklin, TN,
USA). Tricalcium phosphate (β-TCP) with a particulate size
ranging from 1 to 2mm in diameter was obtained from
OrthoVita (Malvern, PA, USA). A matrix consisting of trical-
cium phosphate (β-TCP) combined with soluble type I col-
lagen was obtained from Kensey-Nash Corporation (Exton,
PA, USA).
3.In Vivo Testing
3.1. Repeated Administration of rhPDGF-BB and Bone
Responses. The experimental design for this study was mod-
eled after that of Knight et al. [9] to evaluate bone responses
immediately following repeated injections of rhPDGF-BB.
The study was modiﬁed to determine bone responses at 24
hours and 6 weeks following the last rhPDGF-BB injection
to assess the reversibility of acute tissue responses. The
reversibility of bone responses to multiple-dose injections of
rhPDGF-BB was evaluated using 80 rats (Fischer 344): 40
females (F) and 40 males (M) were divided into 8 groups
consisting of 10 animals each (5 M and 5 F). Dose groups
received injections of the negative control 20mM sodium
acetate, pH 6.0, or 10μg/mL, 30μg/mL, or 100μg/mL
rhPDGF-BB in 20mM sodium acetate, pH 6.0 every other
d a y( i . e . ,d a y s1 ,3 ,5 ,7 ,9 ,1 1 ,a n d1 3 ) .I n j e c t i o n so f0 . 1m L
were made between the ﬁrst and second proximal metatarsi
and at the lateral surface of the femur. Four groups of
a n i m a l s( 1 0ra t spe rgr o u p )w e r es a c ri ﬁ c e do n ed a yf o ll o wi n g
the last injection and the remaining 4 groups (10 rats per
group) were sacriﬁced 6 weeks after the ﬁnal injection. The
right leg (including femora and metatarsi and a minimum
of 5mm margin of overlying soft tissues) of each rat was
recovered at necropsy and ﬁxed in 10% neutral-buﬀered
formalin, decalciﬁed, embedded in paraﬃn, and sectioned
to 10μm thickness. Transverse tissue sections were stained
with hematoxylin and eosin and Masson’s trichrome stain.
Histopathological assessments of the bone and overlying soft
tissues were conducted by a board-certiﬁed histopathologist.
3.2. Systemic Toxicology of rhPDGF-BB Alone or Combined
with β-TCP or a Collagen/β-TCP Matrix. Toxicology studies
were conducted on rhPDGF-BB alone and on two prod-
ucts formulated with rhPDGF-BB that are designed for
bone regeneration: rhPDGF-BB combined with β-TCP and
rhPDGF-BB combined with collagen/β-TCP. Systemic toxi-
city was determined for extracts of 1.0mg/mL rhPDGF-BB
combined with particulate β-TCP (1-2mm mean diameter)
or a 20% w/w bovine type I collagen/80% w/w β-TCP (100–
300μm mean diameter). Extracts of the mixed materials
were tested for bioreactivity due to leachable substances as
described in the following subsections.
3.2.1. Systemic Injection. Based on guidelines provided in
the U.S. Pharmacopeia [10], a 1:1 v/v combination of either
1.0mg/mL rhPDGF-BB with β-TCP or β-TCP alone was
extracted with either 0.9% sodium chloride (NaCl), ethanol
(diluted 1:20 in 0.9% NaCl), polyethylene glycol (PEG), or
cotton seed oil (CSO). Na¨ ıve male albino Swiss mice (Mus
musculus) were either injected intravenously with saline or
ethanol extracts, or intraperitoneally with PEG and CSO
extracts, and observed for signs of toxicity at 0, 4, 24, 48,
and 72 hours after injection. The same testing procedure
was performed using NaCl and CSO extracts of a 3:1 liquid
volume to solid mass combination of 1.0mg/mL rhPDGF-
BB and collagen/β-TCP matrix. Unrestricted rhPDGF-BB
(0.3mg/mL in 20mM sodium acetate, pH 6.5) alone was
also injected intraperitoneally, and observations were made
as described above, and also at 96, 120, 144, and 168 hours
after injection.
3.2.2. Pyrogen Testing. Based on guidelines provided [11],
testing for the presence of pyrogens was done on either a
combination of 1.0mg/mL rhPDGF-BB and collagen plus β-
TCP matrix or collagen plus β-TCP matrix only extracted
in a 0.9% NaCl solution. The extracts were assessed for the
presence of chemical pyrogens that can lead to a febrile
response upon intravenous (IV) administration. Na¨ ıve male
and female New Zealand white rabbits were injected IV
with the extracts and body temperature was monitored after
injection for up to 3 hours.
3.2.3. Allergenic Sensitization. Using guidance provided in
ISO 10993-10 [12], extracts of rhPDGF-BB combined with
either β-TCP or collagen/β-TCP matrix or extracts of β-TCPJournal of Tissue Engineering 3
Table 1: Summary of toxicology studies for rhPDGF-BB alone or combined with either β-TCP or collagen together with β-TCP matrix.
Test rhPDGF-BB
alone
Orthovita Vitoss
β-TCP
(250–1000μm)
Skeletal Kinetics
β-TCP (1-2mm)
CAM Implants
β-TCP (1-2mm)
Kensey-Nash collagen
plus β-TCP
(100–300μm)
Bone Toxicity X
Systemic Injection X X X X X
Pyrogenicity X
Dermal Irritation X X X X X
Intramuscular
Implantation-7 days X
Intramuscular
Implantation-4 weeks XX X
Delayed Hypersensitivity X X X
Cytotoxicity X X X X X
Mutagenicity X X X
Hemolytic Properties X
orcollagen/β-TCPmatrixalonewereassayedforallergenicity
using the Kligman maximization test [13]. Hartley guinea
pigs were injected intradermally within a 2 × 4cm rectangu-
lar area over the shoulder with either NaCl or CSO extracts
with or without Freund’s adjuvant, the NaCl or CSO vehicles
alone with or without Freund’s adjuvant, or positive control
dinitrochlorobenzene (DCNB) with or without Freund’s
adjuvant on day zero. Seven days after injection, the skin
over the injected areas was topically challenged with either
the extracts or the appropriate controls, and at twenty-three
days after injection, a second topical challenge was applied
to the ﬂank of each animal. Following each challenge, the
skin reaction was graded according to the Magnusson and
Kligman scale for the appearance of erythema and swelling.
3.3. Local Tissue Responses and Dermal Irritation Elicited
by Extracts of rhPDGF-BB Combined with β-TCP or
aC o l l a g e n / β-TCP Matrix
3.3.1. Tissue Responses and Irritation-Intracutaneous Injec-
tion. Based on guidance provided in the U.S. Pharmacopeia
[10], acute skin irritation due to subcutaneous injection
of extracts of 1.0mg/mL rhPDGF-BB combined with β-
TCP or β-TCP matrix alone were evaluated using NaCl,
CSO, ethanol, and PEG as extraction solvents. Unextracted
rhPDGF-BB (0.3mg/mL in 20mM sodium acetate, pH 6.5)
alone was also injected subcutaneously for evaluation. Four
New Zealand white rabbits received paravertebral injections
lateral to the vertebral bodies with extracts of the experi-
mental materials. Skin reactions were scored for erythema,
edema, and eschar formation and the data were used to
determine responses at the injection sites in each animal.
In addition, New Zealand rabbits were used to determine
acute skin irritation induced by NaCl and CSO extracts
of 1.0mg/mL rhPDGF-BB combined with collagen/β-TCP
matrix or collagen/β-TCP matrix alone.
3.3.2. Intramuscular Responses. Implantation of 1.0mg/mL
rhPDGF-BB combined with β-TCP or β-TCP alone in the
dorsolumbar paravertebral muscle was done in New Zealand
whiterabbits.Controlβ-TCPalonewascombinedwith0.9%
NaClsolution.Muscleresponseswerecomparedtoresponses
elicited by a negative control plastic implanted in the same
animal. After seven days, the implantation sites were har-
vested and processed for histology and a histopathological
analysis was conducted.
In addition, 1.0mg/mL rhPDGF-BB combined with
collagen/β-TCP matrix or 20mM sodium acetate, pH 6.0
combined with collagen/β-TCP matrix were implanted
intramuscularly in another set of rabbits and after four
weeks, implantation sites were excised and processed for
histopathological analysis.
3.4. In Vitro Toxicity Studies
3.4.1. Cytotoxicity. Cytotoxicity assays were conducted
according to ISO 10993-5 guidelines [14]. The cytotoxicity
of 1.0mg/mL rhPDGF-BB combined with β-TCP or
collagen/β-TCP, and β-TCP or collagen/β-TCP alone
were determined by exposing monolayers of L929 mouse
ﬁbroblasts to Minimum Essential medium (MEM) tissue
culture medium extracts of the test materials for 48 hours at
37◦C. The cellular morphology was graded by microscopic
examination for signs of cell rounding, reductions in
intracellular granularity, cell lysis, and gaps in the cellular
monolayer. Moreover, an additional study with L929 mouse
ﬁbroblasts was performed using an agar overlay on the
cells that included the vital dye, neutral red, to determine
cytotoxicity due to diﬀusible substances released from the
MEM extracts or rhPDGF-BB neat soaked into ﬁlter papers
that were placed on top of the agar. Zones of bioreactivity
under the experimental materials were graded according
to whether the cells either were stained and therefore
viable or were unstained and therefore nonviable. Further,4 Journal of Tissue Engineering
Table 2: Summary of bone bioreactivity ratings at the rat metatarsus and femur.
[PDGF-BB] (μg/mL) Average Bone Bioreactivity Rating∗-Metatarsus Average Bone Bioreactivity Rating∗-Femur
2 weeks 8 weeks 2 weeks 8 weeks
100 2.9 0.0 2.6 0.0
30 1.4 0.0 1.2 0.0
10 0.7 0.0 0.9 0.0
0 (Control) 0.0 0.0 0.0 0.0
∗Average Treated Bone scores—Average Control Bone scores. 0–1.5 = No Reaction, >1.5–3.5 = Mild Reaction, >3.5–6.0 = Moderate Reaction, >6.0 = Marked
Reaction.
determination was made of changes in cell morphology. The
same testing paradigm using L929 mouse ﬁbroblasts was
performed with MEM extracts of 1.0mg/mL rhPDGF-BB
combined with collagen/β-TCP matrix or collagen/β-TCP
matrix alone.
3.4.2. Mutagenicity. Mutagenicity tests were conducted ac-
cording to guidelines provided under ISO 10993-3 [15].
Mutagenic properties of NaCl and CSO extracts of 1.0mg/
mL rhPDGF-BB combined with β-TCP, or collagen/β-
TCP matrices, or collagen/β-TCP combined with 20mM
sodium acetate solution, pH 6.0 were determined using
a reverse mutation assay (Ames test) with mutant strains
of Escherichia coli (E. coli)a n dSalmonella typhimurium
(S. typhimurium) auxotrophic for histidine and tryptophan
biosynthesis. Mutant strains of bacteria (his− and trp−)w e r e
exposed to extracts of the test and control articles for 72
hours. The number of colonies that grew on medium lacking
histidine or tryptophan were counted and compared to
negative controls (extraction solvents) and positive control
mutagenic compounds.
3.4.3. Hemolysis. Hemolysis assays were done according to
guidelines described under ISO 10993-4 [16]. The hemolytic
properties of 0.9% NaCl extracts of 1.0mg/mL rhPDGF-BB
combined with collagen/β-TCP matrix or collagen/β-TCP
matrix alone were determined using blood withdrawn from
a New Zealand white rabbit. Blood was added to the experi-
mental extracts and compared to the negative control saline
or positive control sterile water spectrophotometrically.
4. Results andDiscussion
4.1. In Vivo: Repeated Administration of rhPDGF-BB and
Bone Responses. Acute bone and soft tissue responses to
repeat dosing of rhPDGF-BB at the metatarsi and femora
were determined in rats. Tissue responses were evaluated 24
hours and 6 weeks following the last dose.
Body weights for all animals increased normally during
the injection phase of the study (days 1–13), except for one
female rat receiving 10μg/mL doses of rhPDGF-BB, which
had ∼5% weight loss. Body weights continued to increase
normallyforallratsovertimefollowingthecompletionofall
injections. Swelling was observed at the metatarsal injection
sites on day 14 in all 30 rats receiving rhPDGF-BB and
no swelling was observed in the 10 control rats. Swelling
was temporary and soft tissues overlying the injection sites
returned to normal appearance by 8 weeks in all animals. No
swelling was observed at the femoral injection sites on day
14.
At day 14, no soft tissue reaction was evident at either
the metatarsus or femur for rats receiving either 10μg/mL or
30μg/mL rhPDGF-BB based. A mild inﬂammatory reaction
atthemetatarsuswasobservedonday14inratsthatreceived
100μg/mL rhPDGF-BB, while no reaction occurred in the
soft tissue at the femur. There was no diﬀerence in reactions
at the bone for doses ≤30μg/mL of rhPDGF-BB at either
the metatarsus or the femur. In day 14 rats that received
100μg/mL rhPDGF-BB, a mild bone reaction consisting of
osteogenesis and ﬁbroplasia in the periosteal cortex was
observed. No ectopic bone formation was observed in tissues
near either the femur or metatarsus for any animal. By
8 weeks, the bone remodeling observed at 2 weeks with
the 100μg/mL rhPDGF-BB dose had resolved to normal
appearance and no osteogenic activity was observed.
The results of multiple injections of rhPDGF-BB in rats
led to a mild acute soft tissue inﬂammatory response and
minimal bone formation and ﬁbroplasia in the periosteal
cortex at both metatarsal and femoral injection sites. This
observation occurred only in rats receiving 100μg/mL
rhPDGF-BB. This result was not unexpected, given that
rhPDGF-BB functions to initiate the wound healing process
as a potent chemotactic and mitogenic agent for mesenchy-
mally derived cell types. After a recovery period of 6 weeks
following the ﬁnal injection of rhPDGF-BB, soft tissues, and
bone were normal (Table 2).
Data at 14 days following repeated injections near the
metatarsi and femora of rats were consistent with data previ-
ously reported for rhPDGF-BB (Becaplermin/Regranex) [9].
Moreover, the outcome of rhPDGF-BB on soft and hard
tissues at 2 weeks at both sites was completely reversed
by 6 weeks. This underscores the reversibility of the tissue
response to PDGF when its administration is discontinued.
Lastly, no ectopic bone formation was observed.
4.2. Systemic Toxicology of rhPDGF-BB Alone or in Combi-
nation with β-TCP or a Collagen/β-TCP Matrix. Systemic
injections of rhPDGF-BB alone, NaCl, CSO, ethanol, and
PEG extracts of rhPDGF-BB plus β-TCP or NaCl and CSO
extracts of rhPDGF-BB plus collagen combined with β-TCP
matrix, or similar extracts of control materials showed no
signs of toxicity in any animal. All animals gained weightJournal of Tissue Engineering 5
Table 3: Summary of systemic toxicity studies for rhPDGF-BB combined with β-TCP or collagen/β-TCP.
Strain/Species Route of
Administration∗ Test Article Control
Article(s)
Solvent for
Extraction†
Number per
Dose Summary of Results
Swiss
albino/mouse
IV
IP
1.0mg/mL
rhPDGF-BB +
β-TCP
β-TCP alone
and plastic
NaCl Ethanol
CSO PEG
5 males per
extract
(i) No systemic toxicity
(ii) Body weights increased
in all animals
Swiss
albino/mouse
IV
IP
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collagen/β-
TCP
alone
NaCl CSO 10 animals per
extract
(i) No systemic toxicity
(ii) Body weights increased
in all animals
New Zealand
white/rabbit IV
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collagen/
β-TCP alone
and NaCl
vehicle
NaCl
3 animals per
extract, 1 animal
for NaCl control
(i) No signiﬁcant febrile
reaction in any animal
(ii) No extractable
pyrogens present
Hartley guinea
pigs ID
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collagen/β-
TCP alone,
NaCl and
CSO vehicles,
DNCB
positive
control
NaCl CSO
20 animals per
test extract 10
animals for
negative
controls 5
animals for
positive controls
(i) Body weights increased
(ii) No systemic toxicity
(iii) No erythema or
swelling observed after
topical challenges
(iv) No allergic
sensitization to test article
∗Abbreviations: IV: intravenous, IP: intraperitoneal, ID: intradermal.
†Abbreviations: NaCl: 0.9% sodium chloride, CSO: cotton seed oil, PEG: polyethylene glycol, DNCB: dinitrochlorobenzene.
during the studies. Details of the studies are provided in the
sections below.
4.2.1. Pyrogen Testing. Rabbits injected with extracts of
rhPDGF-BBcombinedwitheitherβ-TCPorcollagen/β-TCP
were evaluated for increases in body temperature due to the
presence of pyrogens. There was no evidence of a febrile
reaction in any of the animals receiving extracts of any of the
test articles. All test and control materials were determined
to be nonpyrogenic.
4.2.2. Allergenic Sensitization. All of the animals gained
weight over the duration of the study and there were
no clinical signs of systemic toxicity in either treated or
control animals. None of the animals treated with NaCl
or CSO extracts of β-TCP combined with rhPDGF-BB, the
collagen with β-TCP matrix combined with rhPDGF-BB,
β-TCP matrix alone, collagen with β-TCP matrix alone, or
extraction vehicle alone showed signs of sensitization or
developed an allergic response. In comparison, extracts of
the positive control dinitrochlorobenzene (DNCB) elicited a
strong allergic response with erythema and swelling at each
topical challenge site.
In summary, in mice and rabbits, NaCl or CSO extracts
of rhPDGF-BB combined with β-TCP or collagen/β-TCP
matrix did not lead to acute or delayed hypersensitivities.
Further, the β-TCP and collagen/β-TCP without rhPDGF-
BB did not lead to hypersensitivity. Moreover, extracts of
1.0mg/mL rhPDGF-BB combined with a collagen/β-TCP
matrix or collagen/β-TCP matrix alone in NaCl or CSO did
not elicit an allergic response after an induction phase in
guinea pigs.
Study designs and data for systemic toxicity testing are
summarized in Table 3.
4.3. Local Tissue Responses and Dermal Irritation Elicited by
Extracts of rhPDGF-BB Combined with Either β-TCP or
aC o l l a g e n / β-TCP Matrix
4.3.1. Tissue Responses and Irritation-Intracutaneous Injec-
tion. In studies with NaCl, ethanol, CSO, or PEG extracts of
rhPDGF-BB combined with β-TCP, or NaCl or CSO extracts
of rhPDGF-BB combined with collagen/β-TCP, there were
no signs ofskinirritation suchaserythema,edema,or eschar
formation in any animal injected intracutaneously. Intracu-
taneous injection of rhPDGF-BB leads to slight irritation of
the skin in rabbits compared to saline controls. This is an
expected response given that rhPDGF-BB is a chemotactic
and mitogenic agent for mesenchymally derived cells and
cells involved in the inﬂammatory cascade that function to
initiate normal wound healing.
4.3.2. Intramuscular Implantation. Intramuscular implanta-
tion of extracts of rhPDGF-BB combined with either β-
TCP or collagen/β-TCP matrices was performed in rabbits
to evaluate acute soft tissue responses to the test articles.
Each test article elicited a mild inﬂammatory response
involving small numbers of polymorphonuclear leukocytes,
macrophages, giant cells, and ﬁbroblasts associated with
the test article implant. RhPDGF-BB is a chemoattractant
for macrophages, monocytes, and ﬁbroblasts, consequently,
this observation was expected given the known biological
properties of PDGF. However, the tissue response elicited
by the experimental material was mild and similar to that
of the plastic implant used as a negative control, and thus,6 Journal of Tissue Engineering
Table 4: Summary of local irritation and implantation studies for rhPDGF-BB combined with β-TCP or collagen/β-TCP.
Strain/Species Route of
Administration∗ Test Article Control
Article(s)
Solvent for
Extraction† Number per Dose Summary of Results
New Zealand
white/rabbits SC
1.0mg/mL
rhPDGF-BB
+ β-TCP
β-TCP alone
and vehicle
NaCl Ethanol
CSO PEG
4 animals, 5
injections per test
article extract
No signs of erythema,
edema, or eschar
formation
New Zealand
white/rabbits SC
1.0mg/mL
rhPDGF-BB
+ collagen/
β-TCP
collagen/
β-TCP alone
and plastic
NaCl CSO
2 animals, 5
injections per test
article extract
No signs of erythema,
edema, or eschar
formation
New Zealand
white/rabbits IM
1.0mg/mL
rhPDGF-BB
+ β-TCP
β-TCP alone
and plastic
None-test and
controls
implanted neat
2 animals, 5
paravertebral
implants per
animal
Endpoint 7 days
(i) Mild cellular
inﬁltration including
PMNs, macrophages,
giant cells, and
ﬁbroblasts
(ii) No signiﬁcant
tissue response over
negative control
plastic
New Zealand
white/rabbits IM
1.0mg/mL
rhPDGF-BB
+ collagen/
β-TCP
collagen/
β-TCP alone
and plastic
None-test and
controls
implanted neat
3 animals, 5
paravertebral test
implants per
animal
Endpoint 28 days
(i) Mild cellular
inﬁltration including
PMNs, macrophages,
giant cells, and
ﬁbroblasts
(ii) No signiﬁcant
tissue response over
negative control
plastic
∗Abbreviations: SC: subcutaneous, IM: intramuscular.
†Abbreviations: NaCl: 0.9% sodium chloride, CSO: cotton seed oil, PEG: polyethylene glycol.
noneofthetestarticleextractselicitedasigniﬁcantbiological
response following intramuscular implantation.
In summary, extracts of 1.0mg/mL rhPDGF-BB com-
bined with either β-TCP or a collagen/β-TCP matrix, or
β-TCP or collagen/β-TCP matrix alone did not cause acute
skin irritation following subcutaneous injection in rab-
bits. In addition, intramuscular implantation of 1.0mg/mL
rhPDGF-BB combined with either β-TCP or collagen/β-
TCP or either of these materials alone did not elicit any
signiﬁcant tissue responses when compared to implanted
negative controls. Study designs and results are summarized
in Table 4.
4.4. In Vitro Toxicity Studies: Cytotoxicity, Mutagenicity,
and Hemolysis
4.4.1. Cytotoxicity. A f t e r4 8h o u r s ,n os i g n so fc y t o t o x i c i t y
were noted for MEM tissue culture medium extracts of
rhPDGF-BB combined with β-TCP, β-TCP alone or the
plastic used as negative control. In distinction, severe
cytotoxicity occurred with extracts from the natural rubber
used as positive control. For the second test using the agar
overlay method, no zones of bioreactivity were seen after
48 hours of incubation with either experimental material
or negative control plastic extracted in MEM tissue culture
medium absorbed into the ﬁlter paper.
MEM tissue culture medium extracts of rhPDGF-BB
combined with collagen/β-TCP matrix or collagen/β-TCP
matrix alone, after 48 hours, had slight bioreactivity con-
sisting of loosely attached, rounded cells lacking intracyto-
plasmic granules and, rarely, lysed cells. No bioreactivity was
observed for extracts of the plastic used as negative control
compared with severe bioreactivity for the natural rubber
used as positive control. The cellular response to the test
materialswasnotunexpected.ThebovinetypeIcollagenwas
modiﬁed to be water soluble and consequently may compete
with the tissue culture plastic for cellular adhesion binding
sitesonthecellsurfaces.Thiseﬀectmaycausecellstobecome
morelooselyattachedtothetissuecultureplastic.Therewere
nocytotoxicoutcomeselicitedbytheexperimentalmaterials.
The data are summarized in Table 5.
4.4.2. Mutagenicity. The mutagenic properties of NaCl and
CSO extracts of rhPDGF-BB combined with collagen/β-TCP
or collagen/β-TCP alone were evaluated using the Ames
test with strains of E. coli and Salmonella typhimurium
that were auxotrophic for histidine or tryptophan. There
were no statistically signiﬁcant (P ≤ .05) increases in the
number of revertant colonies following exposure to the test
article extracts compared to negative controls. Thus, extracts
of rhPDGF-BB combined with collagen/β-TCP matrix or
collagen/β-TCP matrix were nonmutagenic in the bacterial
assays. The data are summarized in Table 5.Journal of Tissue Engineering 7
Table 5: Summary of in vitro toxicity studies for rhPDGF-BB combined with β-TCP or collagen/β-TCP.
Cell Line/Strain Route of
Administration Test Article Control Articles Solvent for
Extraction†
Number per
Dose Summary of Results
L929 mouse
ﬁbroblasts
Direct Contact or
Agar Diﬀusion
1.0mg/mL
rhPDGF-BB +
β-TCP
β-TCP alone
and vehicle
MEM tissue
culture medium
3ﬂ a s k sp e r
extract
(i) No signs of cytotoxicity
(ii) No zones of
bioreactivity
L929 mouse
ﬁbroblasts Direct Contact
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collage/β-TCP +
sodium acetate
solution
MEM tissue
culture medium
3ﬂ a s k sp e r
extract
(i) Few loosely attached
cells or lysed cells with or
without rhPDGF-BB
(ii) No signiﬁcant
cytotoxicity
S. typhimurium
strains TA98,
TA100, TA1535,
TA1537 his−E.
coli strain WP2
trp−
Top agar overlay,
+/− microsomal
metabolic
activation
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collage/β-TCP +
sodium acetate
solution
NaCl and CSO 3p l a t e sp e r
extract
(i) No signiﬁcant increase
in revertant colonies for
test or control article
(ii) Nonmutagenic
Blood from New
Zealand white
rabbit
Direct Contact
1.0mg/mL
rhPDGF-BB +
collagen/β-TCP
collage/β-TCP +
sodium acetate
solution
NaCl 3t e s t sp e r
extract
(i) 2.9% hemolysis
compared to positive
control for test article
(ii) 2.5% hemolysis
compared to positive
control for control article
(iii) Test and control article
nonhemolytic
†Abbreviations: MEM: Modiﬁed Eagle medium, NaCl: 0.9% sodium chloride, CSO: cotton seed oil.
4.4.3. Hemolysis. NaCl extracts of rhPDGF-BB combined
with collagen/β-TCP or collagen/β-TCP alone, resulted in
2.9% hemolysis compared to positive controls. The extracts
of the matrix alone resulted in 2.5% hemolysis. Both materi-
als were considered nonhemolytic compared to controls.
5. Conclusion
The safety and biocompatibility of rhPDGF-BB alone or
in combination with either β-TCP, or a bovine type I
collagen/β-TCP matrix were demonstrated following exten-
sive in vivo and in vitro toxicological and biocompatibility
testing. The experimental materials were not mutagenic,
hemolytic, cytotoxic, pyrogenic, or allergenic. There was
evidence of neither local nor systemic toxicity and all com-
binations of rhPDGF-BB with the materials tested were bio-
compatible following intramuscular implantation. Repeated
administration of rhPDGF-BB delivered by intramuscular
injection near the metatarsi and femora of rats at a dose of
100μg/mL led to elevated bone remodeling and soft tissue
responses. However, 6 weeks after the last injection, bone
remodeling and soft tissues returned to a normal baseline
state. This outcome underscores the normal, reversible eﬀect
of rhPDGF-BB on bone and overlying soft tissues, and
further underscores the safety of the products evaluated in
this paper which intended clinical use is as a single-dose,
locally implanted materials for periodontal and orthopedic
tissue repair.
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